[Arterial hypertension with multiple organ damage: A new entity?]

Sophie Kuntz1, Romain Boulestreau2, Sébastien Rubin3

  • 1CHU de Bordeaux, hôpital Saint-André, 1, rue Jean-Burguet, 33000 Bordeaux, France.

Presse Medicale (Paris, France : 1983)
|October 9, 2018
PubMed

Insights

Hypertensive emergencies, a condition with stable or increasing incidence, require prompt diagnosis and management. Early intervention improves outcomes, even without visible eye damage, to prevent multi-organ damage.

Area of Science:

  • Cardiology
  • Nephrology
  • Ophthalmology

Background:

  • Hypertensive emergency incidence remains stable or is increasing, often underdiagnosed.
  • Early and specific management significantly improves patient prognosis.
  • Diagnosis should not be delayed by the absence of eye damage or fundus examination access.

Purpose of the Study:

  • To define and highlight the importance of managing hypertensive emergencies.
  • To introduce a new definition for Multi-Organ Damage Hypertension.
  • To emphasize timely diagnosis and intervention regardless of ocular findings.

Main Methods:

  • Review of existing literature and clinical guidelines on hypertensive emergencies.
  • Analysis of diagnostic criteria and management strategies.
  • Definition of Multi-Organ Damage Hypertension based on blood pressure and target organ involvement.

Main Results:

  • Hypertensive emergencies have a stable or increasing incidence, with many cases being underdiagnosed.
  • Effective management is crucial for improving prognosis.
  • Multi-Organ Damage Hypertension is defined by a sudden, persistent blood pressure rise without a specific threshold, affecting at least three target organs (brain, heart, kidney, endothelium) or causing ocular involvement.

Conclusions:

  • Prompt diagnosis and management of hypertensive emergencies are critical for better outcomes.
  • The absence of ocular findings should not impede the diagnosis of hypertensive emergency.
  • Multi-Organ Damage Hypertension represents a severe hypertensive state requiring immediate attention and intervention.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
605
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
467
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
509
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
619
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
534
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
879